¹Virendra Tangri, ²Ashok Kumar, ³Anurag Prakash S, ⁴Neeraj Kumar, ⁵Bhupinder singh

¹,²DIT University -Department of Pharmacy, Dehradun, Uttarakhand

³,⁴Department of Pharmacy, Maya College of Pharmacy, Dehradun, Uttarakhand

⁵Global institute of pharmaceutical education & research, Uttarakhand

Nicotinic acid is used to treat dyslipidemia from the past few decades. Nicotinic acid has the capability to increase plasma HDL cholesterol concentration, and so it is being used as a potential pharmacological agent. Nicotinic acid has an unwanted side effect called flushing, which effect the patients compliance as this is unpleasant . With the help of receptor GPR109A for nicotinic acid it is possible to understand the underlying mechanism of action and effects of nicotinic acid, and this helped in maximizing the potential pharmacological effects of nicotinic acid and reducing the flushing side effects.GPR109A is a G protein coupled receptor which is activated by nicotinic acid (NA).The role of GPR109A receptor in the efficacy of nicotinic acid is discussed in this paper.

1) Carlson LA. Nicotinic acid: the broad-spectrum lipid drug. A 50th anniversary review. J Intern Med. 2005;258(2):94–114.
2) Meyers CD, Kamanna VS, Kashyap ML. Niacin therapy in atherosclerosis. Curr Opin Lipidol. 2004;15(6):659–665.
3) Altschul R. Die Beeinflussung des Blutcholesterinspiegels und der experimentellen Ahterosklerose durch Nikotinsäure. Ztschr f Kreislaufforsch. 1956;45:453–460.
4) Brattsand R, Lundholm L. The effect of nicotinic acid and pentaerythritolteranicotinate upon experimental atherosclerosis in the rabbit. Atherosclerosis. 1971;14(1):91–105.
5) Lundholm L, Jacobsson L, Brattsand R, Magnusson O. Influence of nicotinic acid, niceritrol and beta-pyridylcarbinol on experimental hyperlipidemia and atherosclerosis in mini-pigs. Atherosclerosis. 1978;29(2):217–239.
6) Parwaresch MR, Haacke H, Mader C. Efficacy of hypolipidemic treatment in inhibition of experimental atherosclerosis: the effect of nicotinic acid and related compounds. Atherosclerosis. 1978;31(4):395–401.
7) Weitzel G, Wahl P, Buddecke E. Anti-atherosclerotic action of vitamin A compounds, nicotinic acid, beta-pyridyl compounds and arachidonic acid. Hoppe Seylers Z Physiol Chem. 1962;327:109–127.
8) ϖst C–R. Regression of atherosclerosis during nicotinuic acid therapy: a study in man by means of repeated arteriographies. In: Altschul R, ed. Niacin In Vascular Disorders And Hyperlipemia . Springfield, Illinois, USA: Charles C. Thomas Publisher, LTD; 1964:245–262.
9) Blankenhorn DH, Johnson RL, Nessim SA, Azen SP, Sanmarco ME, Selzer RH. The Cholesterol Lowering Atherosclerosis Study (CLAS): design, methods, and baseline results. Control Clin Trials. 1987;8(4):356–387. View this article via: PubMed CrossRef Google Scholar
10) Knopp R. Evaluating niacin in its various forms. Am J Cardiol 86: 51L–56L, 2000.
11) Taylor AJ, Sullenberger LE, Lee HJ, Lee JK, Grace KA. Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins. Circulation 110: 3512–3517, 2004.
12) Knopp R, Ginsberg J, Albers JJ. Contrasting effects of unmodified and time-release forms of niacin on lipoproteins in hyperlipidemic subjects: clues to mechanism of action of niacin. Metabolism 34: 642–650, 1985.
13) Westphal S, Borucki K, Taneva E, Makarova R, Luley C. Extended-release niacin raises adiponectin and leptin. Atherosclerosis 193: 361–365, 2007.
14) Plaisance EP, Grandjean PW, Brunson BL, Judd RL. Increased total and high-molecular weight adiponectin after extended-release niacin. Metabolism 57: 404–409, 2008
15) Manne, R., & Devarajan, A. (2020). Development of Nicotinic Acid Controlled Release Tablets with Natural Phenolic Anti-oxidant Polymer by Encapsulation Technique. Journal of Natural Remedies, 20(4), 139-151. [Google Scholar]
16) Canner PL, et al. Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin. J Am Coll Cardiol. 1986;8(6):1245–1255. View this article via: PubMed CrossRef Google Scholar]
17) Gille A, Bodor ET, Ahmed K, Offermanns S. Nicotinic acid: pharmacological effects and mechanisms of action. Annu Rev Pharmacol Toxicol. 2008;48:79-106. [PubMed]
18) Montecucco F, Quercioli A, Dallegri F, Viviani GL, Mach F. New evidence for nicotinic acid treatment to reduce atherosclerosis. Expert Rev Cardiovasc Ther. 2010 Oct;8(10):1457-67. [PubMed]
19) Meyer-Ficca M, Kirkland JB. Niacin. Adv Nutr. 2016 May;7(3):556-8. [PMC free article] [PubMed]
20) Li J, Qu J, Shi Y, Perfetto M, Ping Z, Christian L, Niu H, Mei S, Zhang Q, Yang X, Wei S. Nicotinic acid inhibits glioma invasion by facilitating Snail1 degradation. Sci Rep. 2017 Mar 03;7:43173. [PMC free article] [PubMed]
21) Yang X, Mei S, Niu H, Li J. Nicotinic acid impairs assembly of leading edge in glioma cells. Oncol Rep. 2017 Aug;38(2):829-836. [PMC free article] [PubMed]
22) Offermanns S (2006) The nicotinic acid receptor GPR109A (HM74A or PUMA-G) as a new therapeutic target. Trends in Pharmacological Sciences 27: 384–390.View Article Google Scholar
23) Digby JE, Ruparelia N, Choudhury RP (2012) Niacin in Cardiovascular Disease: Recent Preclinical and Clinical Developments. Arteriosclerosis, Thrombosis, and Vascular Biology 32: 582–588. View Article Google Scholar
24) Digby JE, McNeill E, Dyar OJ, Lam V, Greaves DR, et al. (2010) Anti-inflammatory effects of nicotinic acid in adipocytes demonstrated by suppression of fractalkine, RANTES, and MCP-1 and upregulation of adiponectin. Atherosclerosis 209: 89–95. View Article Google Scholar
25) Digby JE, Martinez F, Jefferson A, Ruparelia N, Chai JT, et al. (2012) Anti-Inflammatory Effects of Nicotinic Acid in Human Monocytes Are Mediated by GPR109A Dependent Mechanisms. Arterioscler Thromb Vasc Biol 32: 669–676.
26) Lukasova M, Malaval C, Gille A, Kero J, Offermanns S (2011) Nicotinic acid inhibits progression of atherosclerosis in mice through its receptor GPR109A expressed by immune cells. Journal of Clinical Investigation 121: 1163–1173.
27) Guyton, JR. Extended-release niacin for modifying the lipoprotein profile. Expert Opin. Pharmacother. 2004. 5:1385-1398. View this article via: PubMed Google Scholar
28) Tornvall, P, Walldius, G. A comparison between nicotinic acid and acipimox in hypertriglyceridaemia – effects on serum lipids, lipoproteins, glucose tolerance and tolerability. J. Intern. Med. 1991. 230:415-421. View this article via: PubMed Google Scholar
29) Schaub, A, Futterer, A, Pfeffer, K. PUMA-G, an IFN-gamma-inducible gene in macrophages is a novel member of the seven transmembrane spanning receptor superfamily. Eur. J. Immunol. 2001. 31:3714-3725. View this article via: PubMed Google Scholar
30) Carlson, LA. Nicotinic acid and inhibition of fat mobilizing lipolysis. Present status of effects on lipid metabolism. Adv. Exp. Med. Biol. 1978. 109:225-238.
31) Benyó Z, Gille A, Kero J, Csiky M, Suchankova MC, Nusing RM et al. (2005). GPR109A (PUMA‐G/HM74A) mediates nicotinic acid‐induced flushing. J Clin Invest 115: 3634–3640.
32) Maciejewski‐Lenoir D, Richman JG, Hakak Y, Gaidarov I, Behan DP, Connolly DT (2006). Langerhans cells release prostaglandin D2 in response to nicotinic acid. J Invest Dermatol 126: 2637–2646.
33) Benyó Z, Gille A, Bennett CL, Clausen BE, Offermanns S (2006). Nicotinic acid‐induced flushing is mediated by activation of epidermal langerhans cells. Mol Pharmacol 70: 1844–1849.
34) Stern, R. H. (2007). The role of nicotinic acid metabolites in flushing and hepatotoxicity. Journal of clinical lipidology, 1(3), 191-193.
35) Bodor, E. T., & Offermanns, S. (2008). Nicotinic acid: an old drug with a promising future. British journal of pharmacology, 153(S1), S68-S75.
36) Plaisance, E. P., Lukasova, M., Offermanns, S., Zhang, Y., Cao, G., & Judd, R. L. (2009). Niacin stimulates adiponectin secretion through the GPR109A receptor. American Journal of Physiology-Endocrinology and Metabolism, 296(3), E549-E558.

VOLUME 04 ISSUE 05 MAY 2021